Reviva Reports First Quarter 2025 Financial Results and Recent Business Highlights
- Successful completion of OLE trial with 446 participants, meeting FDA requirement of 100 patients for 12-month safety data
- Reduced net loss to $6.4 million in Q1 2025 from $7.4 million in Q1 2024
- Clear regulatory pathway with NDA submission targeted for Q4 2026
- Expansion potential with planned IND submission for brilaroxazine in psoriasis
- Cash position declined significantly from $13.5M to $5.3M in one quarter
- Phase 3 RECOVER-2 trial initiation dependent on securing additional financing
- Continued quarterly losses affecting financial stability
Insights
Reviva's brilaroxazine shows positive momentum in schizophrenia, but cash position warrants attention amid upcoming Phase 3.
Reviva's Q1 update reveals substantial progress for their lead asset brilaroxazine in schizophrenia, with 446 patients having completed the long-term open-label extension (OLE) trial. Most importantly, 156 patients reached the critical one-year treatment milestone, with 301 patients completing six months. This one-year data from at least 100 patients is crucial as it satisfies a key FDA requirement for the eventual NDA submission.
The company is targeting several near-term catalysts that could significantly impact valuation. The full OLE dataset expected in Q2 2025 will provide comprehensive insights into brilaroxazine's long-term safety, efficacy, adherence, and biomarker profile. Additionally, Reviva plans to initiate the registrational Phase 3 RECOVER-2 trial by mid-2025, contingent upon securing additional financing.
The financial position raises concerns. Cash and equivalents stood at
Beyond schizophrenia, Reviva is expanding brilaroxazine's potential with plans to submit an IND for a liposomal-gel formulation in psoriasis later in 2025, indicating efforts to build a broader pipeline and potentially diversify risk. The company is also actively pursuing partnership opportunities, which could provide non-dilutive funding and validation of their technology.
Brilaroxazine's strong OLE completion rates and biomarker data signal promising clinical profile for schizophrenia treatment.
The completion of Reviva's long-term open-label extension (OLE) trial represents a significant milestone in brilaroxazine's development pathway. The robust patient retention—with 446 total completers, including 156 reaching one year and 301 completing six months—suggests promising tolerability. In schizophrenia trials, where dropout rates are notoriously high due to side effects or perceived lack of efficacy, this level of completion warrants attention.
What's particularly noteworthy is Reviva's incorporation of biomarker analyses in the trial design. While traditional schizophrenia drug development relies heavily on clinical rating scales, the inclusion of both vocal and blood biomarkers represents a more modern approach to independently validate both safety and efficacy claims. These objective measures could potentially strengthen brilaroxazine's regulatory package by providing mechanism-based evidence beyond subjective clinical assessments.
The company's characterization of brilaroxazine as having a "differentiated and promising therapeutic profile" likely refers to its pharmacological mechanism as a serotonin-dopamine signaling modulator. The mention of a "compelling drug-drug interaction study" suggests favorable metabolic properties—a critical factor for schizophrenia medications often taken concomitantly with other drugs. This could potentially address a significant limitation of many existing antipsychotics.
The late-breaking presentation at ASCP and their recent oral presentation at SIRS—both prestigious neuropsychopharmacology conferences—indicate the scientific community's interest in this compound. The timing of the projected NDA submission in Q4 2026 suggests Reviva anticipates the second Phase 3 trial (RECOVER-2) will take approximately 15-18 months to complete once initiated, which aligns with typical timelines for pivotal schizophrenia trials.
– 446 participants completed the brilaroxazine long-term open-label extension (OLE) trial with 156 completing one-year and 301 completing six months of treatment –
– Full data set from RECOVER OLE highlighting clinical response, safety, efficacy, adherence, and biomarker data expected in Q2 2025 –
– Registrational Phase 3 RECOVER-2 trial initiation for brilaroxazine expected mid-2025 –
CUPERTINO, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today reported financial results for the first quarter ended March 31, 2025 and summarized recent business highlights.
“Our late stage brilaroxazine program is advancing towards registration and we are excited for our important near-term catalysts ahead. Notably, the full dataset from our global OLE trial will include data from 446 participants of which 156 have completed at least one-year of treatment. We look forward to reporting clinical response, safety, adherence, and biomarker data in the second quarter of the year,” said Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva. “Brilaroxazine continues to demonstrate what we believe is a differentiated and promising therapeutic profile across our robust data package that is expected to include a successful placebo-controlled Phase 3 trial with a long-term open label extension for up to 1-year, a successful Phase 2 study, and a compelling drug-drug interaction study. We believe the findings from these studies reinforce the potential of once daily brilaroxazine to address major unmet needs for patients with schizophrenia, and we are targeting a potential New Drug Application (NDA) submission for brilaroxazine in the fourth quarter of 2026.”
First Quarter 2025 and Recent Business Highlights
Clinical Program Highlights
- Long-term OLE portion of the RECOVER Phase 3 trial is complete
- 446 patients have completed the trial
- 156 patients have completed 1-year (12 months) of treatment
- 301 patients have completed 6 months of treatment
- Biomarkers designed to independently support safety and efficacy
- Long-term safety data from 100 patients who have completed 12 months of treatment is a requirement for brilaroxazine’s NDA submission to the FDA
- Presenting a late-breaking poster presentation on the RECOVER 12-month OLE trial for brilaroxazine in schizophrenia at the 2025 American Society of Clinical Psychopharmacology (ASCP) annual meeting on Wednesday May 28, 2025, in Scottsdale, AZ.
- Positive topline data from the long-term OLE portion of the Phase 3 RECOVER study evaluating brilaroxazine in schizophrenia presented as an oral presentation on March 30th at the 2025 Congress of the Schizophrenia International Research Society (SIRS) in Chicago, Illinois.
Anticipated Milestones and Events
- Full data analysis of the OLE trial including long-term safety, tolerability and efficacy, as well as vocal and blood biomarker data expected in Q2 2025
- Initiation of registrational Phase 3 RECOVER-2 trial evaluating brilaroxazine for the treatment of schizophrenia expected in mid-2025, subject to receipt of additional financing
- Potential NDA submission for brilaroxazine in schizophrenia targeted for the fourth quarter of 2026
- Investigational new drug application (IND) submission for liposomal-gel formulation of brilaroxazine in psoriasis expected later in 2025
- Pursue partnership opportunities for the development of our pipeline
Financial Results for March 31, 2025
- The Company reported a net loss of approximately
$6.4 million , or$0.13 per share, for the three months ended March 31, 2025, compared to a net loss of approximately$7.4 million , or$0.25 per share, for the three months ended March 31, 2024.
- As of March 31, 2025, the Company’s cash and cash equivalents totaled approximately
$5.3 million compared to approximately$13.5 million as of December 31, 2024.
About Reviva
Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva's current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva's pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act, as amended, including those relating to the Company’s 1-year open label extension (OLE) trial evaluating the long-term safety and tolerability for brilaroxazine in schizophrenia, the registrational Phase 3 RECOVER-2 trial, the Company’s expectations regarding the anticipated clinical profile of its product candidates, including statements regarding anticipated efficacy or safety profile, and those relating to the Company’s expectations, intentions or beliefs regarding matters including product development and clinical trial plans and the timing thereof, including the anticipated timing of the availability of trial data, clinical and regulatory timelines and expenses, planned or intended additional trials or studies and the timing thereof, planned or intended regulatory submissions and the timing thereof, trial results, market opportunity, ability to raise sufficient funding, competitive position, possible or assumed future results of operations, business strategies, potential opportunities for development including partnerships, growth or expansion opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.
These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential, “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s most recent Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and the Company’s other filings from time to time with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
Corporate Contact:
Reviva Pharmaceuticals Holdings, Inc.
Laxminarayan Bhat, PhD
www.revivapharma.com
Investor Relations Contact:
LifeSci Advisors, LLC
Bruce Mackle
bmackle@lifesciadvisors.com
| REVIVA PHARMACEUTICALS HOLDINGS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) | |||||||
| March 31, | December 31, | ||||||
| 2025 | 2024 | ||||||
| Assets | |||||||
| Cash and cash equivalents | $ | 5,289,404 | $ | 13,476,331 | |||
| Prepaid clinical trial costs | 211,855 | 540,601 | |||||
| Prepaid expenses and other current assets | 756,066 | 666,435 | |||||
| Total current assets | 6,257,325 | 14,683,367 | |||||
| Non-current prepaid clinical trial costs | 819,721 | 819,721 | |||||
| Total Assets | $ | 7,077,046 | $ | 15,503,088 | |||
| Liabilities and Stockholders’ Equity (Deficit) | |||||||
| Liabilities | |||||||
| Short-term debt | $ | 224,300 | $ | 458,154 | |||
| Accounts payable | 4,721,043 | 6,283,430 | |||||
| Accrued clinical expenses | 5,524,163 | 6,723,719 | |||||
| Accrued compensation | 556,884 | 635,587 | |||||
| Other accrued liabilities | 482,864 | 500,616 | |||||
| Total current liabilities | 11,509,254 | 14,601,506 | |||||
| Warrant liabilities | 27,816 | 89,010 | |||||
| Total Liabilities | 11,537,070 | 14,690,516 | |||||
| Commitments and contingencies | |||||||
| Stockholders’ Equity (Deficit) | |||||||
| Common stock, par value of | 4,674 | 4,658 | |||||
| Preferred Stock, par value of | — | — | |||||
| Additional paid-in capital | 166,241,192 | 165,080,964 | |||||
| Accumulated deficit | (170,705,890 | ) | (164,273,050 | ) | |||
| Total stockholders' equity (deficit) | (4,460,024 | ) | 812,572 | ||||
| Total Liabilities and Stockholders’ Equity (Deficit) | $ | 7,077,046 | $ | 15,503,088 | |||
| REVIVA PHARMACEUTICALS HOLDINGS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) | |||||||
| Three Months Ended March 31, | |||||||
| 2025 | 2024 | ||||||
| Operating expenses | |||||||
| Research and development | $ | 4,113,537 | $ | 5,783,865 | |||
| General and administrative | 2,424,630 | 2,138,241 | |||||
| Total operating expenses | 6,538,167 | 7,922,106 | |||||
| Loss from operations | (6,538,167 | ) | (7,922,106 | ) | |||
| Other income (expense) | |||||||
| Gain on remeasurement of warrant liabilities | 61,194 | 456,177 | |||||
| Interest expense | (11,620 | ) | (3,487 | ) | |||
| Interest income | 86,111 | 173,098 | |||||
| Other (expense) income, net | (25,145 | ) | (129,894 | ) | |||
| Total other (expense) income, net | 110,540 | 495,894 | |||||
| Loss before provision for income taxes | (6,427,627 | ) | (7,426,212 | ) | |||
| Provision for income taxes | 5,213 | 7,396 | |||||
| Net loss | $ | (6,432,840 | ) | $ | (7,433,608 | ) | |
| Net loss per share: | |||||||
| Basic and diluted | $ | (0.13 | ) | $ | (0.25 | ) | |
| Weighted average shares outstanding | |||||||
| Basic and diluted | 48,644,339 | 29,887,325 | |||||
FAQ
What are the key results from RVPH's brilaroxazine OLE trial in schizophrenia?
What is Reviva's (RVPH) current cash position and financial performance in Q1 2025?
When does Reviva plan to submit the NDA for brilaroxazine?
What are the next major milestones for RVPH's brilaroxazine development?
What additional indications is Reviva (RVPH) exploring for brilaroxazine?
